Short answer
Kyverna Therapeutics Inc (KYTX) filed an 8-K current report with the SEC on July 27, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). ElevateBio remains Kyverna’s manufacturing partner for miv-cel, now covering clinical and commercial supply.
Kyverna Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- ElevateBio remains Kyverna’s manufacturing partner for miv-cel, now covering clinical and commercial supply
- Agreement replaces the July 2023 manufacturing contract, reducing uncertainty around supply continuity
- Kyverna committed to minimum product quantities in specified years and after regulatory approval, creating future purchase obligations
- Pricing and service fees adjust annually for inflation, capped using Pharmaceutical Preparation Manufacturing PPI data
- Five-year initial term with automatic one-year renewals, subject to termination rights and uncured material breach conditions
Item 7.01 · Regulation FD Disclosure
- Kyverna and ElevateBio announced a new agreement on July 27, 2026
- Agreement terms and strategic implications require review of Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- ElevateBio agreement secures flexible, scalable U.S. commercial and global clinical manufacturing for miv-cel
- Manufacturing support targets potential launches in stiff person syndrome and generalized myasthenia gravis
- Kyverna remains on track to complete rolling SPS BLA submission in Q4 2026
- ElevateBio reports more than 98% clinical manufacturing success rate for miv-cel
- Commercial supply readiness reduces a key execution risk if FDA approves miv-cel
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kyverna Therapeutics Inc 8-K filings
Get the next KYTX 8-K as it lands
Follow KYTX for push alerts, or ask the research agent what this filing means.